Docetaxel-based combination therapy for castration-resistant prostate cancer (Q37721016)

22 August 2017

1 reference

title

Docetaxel-based combination therapy for castration-resistant prostate cancer (English)

1 reference

22 August 2017

1 reference

M D Galsky

1

1 reference

PubMed ID

20351071

22 August 2017

N J Vogelzang

series ordinal

2

1 reference

22 August 2017

29 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

21

1 reference

22 August 2017

2135-2144

1 reference

22 August 2017

11

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

22 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Phase II study of sunitinib in men with advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Endothelin receptor A blockade enhances taxane effects in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ050

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ050

1 reference

22 August 2017

1 reference

PubMed ID

20351071